What is Synthonics?
Synthonics Inc. is a global innovator in the field of Metal Coordinated Pharmaceuticals (MCPs), dedicated to revolutionizing the efficacy and absorption of metal-based drugs. The company's proprietary technology, supported by four active US patents, leverages the unique properties of transition metals to create novel drug formulations. Synthonics has demonstrated that its MCP approach can markedly enhance drug absorption and reduce variability in drug delivery, offering advanced solutions for pharmaceutical companies and healthcare providers seeking to improve therapeutic outcomes.
How much funding has Synthonics raised?
Synthonics has raised a total of $500K across 1 funding round:
Private Equity
$500K
Private Equity (2014): $500K, investors not publicly disclosed
What's next for Synthonics?
The recent enterprise-level funding for Synthonics signals a critical juncture for the company, indicating a transition from development to aggressive market penetration and scaling. This strategic investment will likely fuel further research and development, expand manufacturing capabilities, and accelerate the commercialization of its MCP-based drug formulations. The company is poised to solidify its position as a key player in the pharmaceutical sector, driving innovation in drug delivery systems.
See full Synthonics company page
